Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids

British Journal of Cancer

Volumn 91, Issue 3, 2004, Pages 476-481

  Vehmanen, L ^a   Saarto, T ^a   Blomqvist, C ^a   Taskinen, M R ^a   Elomaa, I ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Breast cancer; Chemotherapy; Serum lipids; Tamoxifen

Indexed keywords

CLODRONIC ACID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANISETRON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; METOCLOPRAMIDE; TAMOXIFEN; TROPISETRON;

ADJUVANT CHEMOTHERAPY; AMENORRHEA; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; LIPID BLOOD LEVEL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MENSTRUAL IRREGULARITY; MENSTRUATION; NAUSEA; OVARY INSUFFICIENCY; PREMENOPAUSE; PRIORITY JOURNAL; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLODRONIC ACID; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; LIPOPROTEINS; METHOTREXATE; MIDDLE AGED; OVARIAN FAILURE, PREMATURE; PREMENOPAUSE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 4143051577     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601979     Document Type: Article

References (45)

1. Bass KM, Newschaffer CJ, Klag MJ, Bush TL (1993) Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 153: 2209-2216
2. Bianco AR, Del Mastro L, Gallo C, Perrone F, Matano E, Pagliarulo C, De Placido S (1991) Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer 63: 799-803
3. Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14: 1718-1729
4. Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, Zambetti M, Veronesi U (1985) Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5: 95-115
5. Caleffi M, Fentiman IS, Clark GM, Wang DY, Needham J, Clark K, La Ville A, Lewis B (1988) Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentration and blood clotting parameters in premenopausal women with breast pain. J Endocrinol 119: 335-339
6. Decensi A, Robertson C, Rotmensz N, Severi G, Maisonneuve P, Sacchini V, Boyle P, Costa A, Veronesi U (1998) Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group. Br J Cancer 78: 572-578
7. Del Mastro L, Venturini M, Sertoli MR, Rosso R (1997) Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 43: 183-190
8. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339: 357-363
9. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 339: 1-15 71-85
10. Early Breast Cancer Trialists' Collaborative Group (1998a) Polychemotherapy for early breast cancer: an overview of randomised trials. Lancet 352: 930-942
11. Early Breast Cancer Trialists' Collaborative Group (1998b) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467
12. Fisher B, Constantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel project P-1 Study. J Natl Cancer Inst 90: 1371-1388
13. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502
14. Fukami K, Koike K, Hirota K, Yoshikawa H, Miyake A (1995) Perimenopausal changes in serum lipids and lipopoteins: a 7-year longitudinal study. Maturitas 22: 193-197
15. Grady D, Rueben SB, Pettiti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117: 1016-1037
16. Grey AB, Stapleton JP, Evans MC, Reid IR (1995) The effect of the antiestrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 80: 3191-3195
17. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin replacement Study (HERS) Research Group. JAMA 280: 605-613
18. Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y (1977) Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39: 1403-1409
19. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: 1349-1357
20. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, DeMets DL (1990) Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82: 1327-1332
21. Ludwig Breast Cancer Study Group (1985) A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 45: 4454-4459
22. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, Women's Health Initiative Investigators (2003) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349: 523-534
23. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR (1989) Menopause and risk factors for coronary heart disease. N Engl J Med 321: 641-646
24. McDonald CC, Stewart HJ (1991) Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 303: 435-437
25. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M (1993) Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 328: 1069-1075
26. Newnhamn HH (1993) Oestrogens and atherosclerotic vascular disease-lipid factors. Bailliere Clin Endocrinol Metab 7: 61-93
27. Padmanabhan N, Wang DY, Moore JW, Rubens RD (1987) Ovarian function and adjuvant chemotherapy for early breast cancer. Eur J Cancer 23: 745-748
28. Powles TJ, Jones AL, Ashley SE, O'Brien ME, Tidy VA, Treleavan J, Cosgrove D, Nash AG, Sacks N, Baum M, McKinna JA, Davey JB (1994) The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31: 73-82
29. Powles TJ, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Mannisto E, Suovuori A, Atula S, Nevalainen J, Pylkkanen L (2002) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20: 3219-3224
30. Pripp U, Hall G, Csemiczky G, Eksborg S, Landgren BM, Schenck-Gustafsson K (1999) A randomized trial on effects of hormone replacement therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease. J Hypertens 17: 1379-1386
31. Reis SE, Costantino JP, Wickerham DL, Tan-Chiu E, Wang J, Kavanah M (2001) Cardiovascular effects of tamoxifen in women with and without heart disease: Breast Cancer Prevention Trial. J Natl Cancer Inst 93: 16-21
32. Richards MA, O'Reilly SM, Howell A, George WD, Fentiman IS, Chaudary MA, Crowther D, Rubens RD (1990) Adjuvant cyclophosphamide, methotrexate and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial. J Clin Oncol 8: 2032-2039
33. Rijpkema AH, van der Sanden AA, Ruijs AH (1990) Effects of postmenopausal estrogen-progesterone therapy on serum lipids and lipoproteins: a review. Maturitas 12: 259-285
34. Rutqvist LE, Mattsson A (1993) Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study. J Natl Cancer Inst 85: 1398-1406
35. Rzymowska J (1999) Effect of cytotoxic chemotherapy on serum lipid levels in breast cancer patients. Pathobiology 67: 129-132
36. Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I (1996a) Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer. J Clin Endocrinol Metab 81: 4453-4457
37. Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I (1996b) Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 14: 429-433
38. Saarto T, Blomqvist C, Virkkunen P, Elomaa I (2001) Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19: 10-17
39. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-1009
40. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
41. Schaefer EJ, Famon-Fava S, Cohn SD, Schaefer MM, Ordovas JM, Castelli WP, Wilson PW (1994) Effects of age, gender, menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in Framingham Offspring Study. J Lipid Res 35: 779-792
42. Stampfer M, Colditz G (1991) Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 20: 47-63
43. Stevenson JC, Crook D, Godsland IF (1993) Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 98: 83-90
44. Subramaniam S, Marar T, Devi CS (1991) Studies on the changes in plasma lipids and lipoproteins in CMF treated breast cancer patients. Biochem Int 24: 1015-1024
45. Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 273: 199-208